Abstract
Existing longitudinal data on patients with classical galactosaemia suggests that neurocognitive functioning is impaired and, in isolated case reports, may show a decline in performance over time. The present study explored whether there are long-term changes in cognitive abilities in patients with galactosaemia and whether oral uridine can improve neurocognitive performance. Thirty-five patients (18 males, 17 females), 29 of whom received oral uridine powder at 150 mg/kg per day (divided dose, three times daily), were evaluated over a 2-5-year period with the Woodcock-Johnson Revised Cognitive Abilities Test, three academic achievement tests, and the Beery Test of Visual Motor Integration. Results showed that the uridine cohort and a comparison group that received only dietary restriction made small gains in cognitive performance over the treatment period and the size of the gains did not differ significantly. Seven subjects who started uridine prior to the age of 14 months did not differ significantly in their cognitive test scores at an average age of 3.5 years from a group of older children who had begun treatment at 4.5 years of age. These results provide no support for any developmental or uridine-treatment-related change in cognitive functioning for this sample of galactosaemic subjects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Beery K (1989) Developmental Test of Visual Motor Integration. Cleveland, OH: Modern Curiculum Press.
Bohles H, Wenzel D, Shin YS (1986) Progressive cerebellar and extrapyramidal motor disturbances in galactosemic twins. Eur J Pediatr 145: 413–417.
Haberlan C, Perou M, Brunngarder EG, Hof H (1991) The neuropathology of galactosemia. J Neuropathol Exp Neurol 30: 431–447.
Irons M, Levy HL, Pueschel S, Castree K (1985) Accumulation of galactose-1-phosphate in the galactosemic fetus despite maternal milk avoidance. J Pediatr 107: 261–263.
Kaufman FR, McBride-Chang C, Manis FR, et al (1995) Cognitive functioning, neurologic sequelae and imaging in classical galactosemia. Eur J Pediatr, 754Suppl. 2: 52–55.
Komrower G, Lee D (1983) Long-term follow-up of galactosemia. J Pediatr 102: 75–77.
Lo W, Packman S, Nash S, et al (1984) Curious neurologic sequelae in galactosemia. Pediatrics 73: 309–312.
Nelson MD, Wolff JA, Cross CA, Donnell GN, Kaufman FR (1992) Galactosemia: evaluation with MR imaging. Radiology 184: 255–261.
Ng WG, Donnell GN, Bergren WR, et al (1977) Prenatal diagnosis of galactosemia. Clin Chim Acta 74: 227–235.
Ng W, Xu Y, Kaufman FR, Donnell GN (1989) Deficit of uridine diphosphate galactose in galactosemia. J Inher Metab Dis 12: 257–266.
Petry K, Greinix HT, Nudelman E, et al (1991) Characterization of a novel biochemical abnormality in galactosemia: deficiency of glycolipids containing galactose or N-acetylgalactosamine and accumulation of precursors in brain and lymphocytes. Biochem Med Metab Biol 46: 93–104.
Shin YS, Rieth M, Hoyer S, Endres W (1985) Uridine diphosphogalactose, galactose-1-phosphate and galactitol concentration in patients with classical galactosemia. Abstracts 23rd SSIEM Annual Symposium Proceedings Inborn Errors of Metabolism, Liverpool, UK, p. 35.
Vannas A, Hogan MJ, Golbas MS, Wood I (1975) Lens changes in galactosemic fetuses. Am J Ophthal 80: 726.
Waggoner DD, Buist NM, Donnell G, et al (1990) Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inher Metab Dis 13: 802–818.
Woodcock R, Johnson M (1989) Woodcock-Johnson Psychoeducational Battery — Revised. Allen, TX: DLM Teaching Resources.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Manis, F.R., Cohn, L.B., McBride-Chang, C. et al. A longitudinal study of cognitive functioning in patients with classical galactosaemia, including a cohort treated with oral uridine. J Inherit Metab Dis 20, 549–555 (1997). https://doi.org/10.1023/A:1005357622551
Issue Date:
DOI: https://doi.org/10.1023/A:1005357622551